OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 14
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 14
Showing 14 citing articles:
20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs
Minmin Qin
ADC Review / Journal of Antibody-drug Conjugates (2025)
Open Access
Minmin Qin
ADC Review / Journal of Antibody-drug Conjugates (2025)
Open Access
The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts
Han Liu, Hongye Zeng, Xiaojing Qin, et al.
Protein & Cell (2025)
Open Access
Han Liu, Hongye Zeng, Xiaojing Qin, et al.
Protein & Cell (2025)
Open Access
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon
Keiji Sugiyama, Ian Chau
Cancer Treatment Reviews (2025) Vol. 133, pp. 102888-102888
Open Access
Keiji Sugiyama, Ian Chau
Cancer Treatment Reviews (2025) Vol. 133, pp. 102888-102888
Open Access
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trails
Zhaohui Huang, Xinyu Li, Xin Zhou, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Zhaohui Huang, Xinyu Li, Xin Zhou, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Development of Antibody–Drug Conjugates for Malignancies of the Uterine Corpus: A Review
T. Yamanaka, Tadaaki Nishikawa, Hiroshi Yoshida
Cells (2025) Vol. 14, Iss. 5, pp. 333-333
Open Access
T. Yamanaka, Tadaaki Nishikawa, Hiroshi Yoshida
Cells (2025) Vol. 14, Iss. 5, pp. 333-333
Open Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development
Lei Wen, Yuanyuan Zhang, Chenxi Sun, et al.
Antibody Therapeutics (2025)
Open Access
Lei Wen, Yuanyuan Zhang, Chenxi Sun, et al.
Antibody Therapeutics (2025)
Open Access
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Cancer Treatment Reviews (2025), pp. 102922-102922
Closed Access
Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Cancer Treatment Reviews (2025), pp. 102922-102922
Closed Access
RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond
Yuan Ding, Cuicui Liu, Ke‐Da Yu
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Yuan Ding, Cuicui Liu, Ke‐Da Yu
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies
Mahsa Mortaja, Stephen Adams, Rana R. McKay, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Mahsa Mortaja, Stephen Adams, Rana R. McKay, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Antibodies to watch in 2025
Silvia Crescioli, Hélène Kaplon, Lin Wang, et al.
mAbs (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Silvia Crescioli, Hélène Kaplon, Lin Wang, et al.
mAbs (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
A High-Affinity Antibody-Drug Conjugates Actuximab-MMAE for Potent and Selective Targeting of CEACAM5-Positive Tumors
Yuqi Hu, Xin Du, Jing Yuan, et al.
Cancer Letters (2025), pp. 217685-217685
Closed Access
Yuqi Hu, Xin Du, Jing Yuan, et al.
Cancer Letters (2025), pp. 217685-217685
Closed Access
Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity
Yun Huang, Wen-Qing Zhong, Xiaoyu Yang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Yun Huang, Wen-Qing Zhong, Xiaoyu Yang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents
Agathe Boos, Julien Most, Héloïse Cahuzac, et al.
Journal of Medicinal Chemistry (2024) Vol. 68, Iss. 1, pp. 695-705
Closed Access | Times Cited: 1
Agathe Boos, Julien Most, Héloïse Cahuzac, et al.
Journal of Medicinal Chemistry (2024) Vol. 68, Iss. 1, pp. 695-705
Closed Access | Times Cited: 1
Harnessing Acylhydrazone-oxime Exchange Reaction to Achieve Diverse Synthesis of Glycosite-specific Antibody-Drug Conjugates
Fei Xia, Zhi Liu, Jiaying Hang, et al.
Organic & Biomolecular Chemistry (2024)
Closed Access
Fei Xia, Zhi Liu, Jiaying Hang, et al.
Organic & Biomolecular Chemistry (2024)
Closed Access
